



## **Tammie Wahaus Bio**

**Tammie Wahaus**, serves as Chief Executive Officer of ELIAS Animal Health, a biotechnology company with Corporate headquarters in Kansas City. ELIAS is advancing a novel targeted T cell-based immunotherapy for the treatment of cancer in the veterinary sector. As founder, she has led the company formation,

strategic planning, business development, and clinical development efforts for ELIAS since 2014. She joined TVAX Biomedical (a human health biotech company) in 2012 as Chief Financial Officer and developed the animal health spin-off strategy that resulted in the formation of ELIAS.

Ms. Wahaus is an experienced business leader with more than twenty-five years of experience serving in leadership roles for both public and private companies. Previously, Ms. Wahaus was an audit partner and national office advisor with Ernst & Young, a major international accounting firm. She also served as Global Controller and Principal Accounting Officer for a GE Global Insurance Holdings (a subsidiary of GE Capital), where she oversaw the global accounting and reporting operations across four continents and implemented Six Sigma Quality process management systems in finance earning a Six Sigma Black Belt certification. She has led successful domestic and international teams focused on the technology, manufacturing and biotechnology industries, and has broad experience in mergers and acquisitions, debt and equity offerings, business integrations and regulatory affairs. She is a long-time member of the Kansas City business community, a strong supporter of the KC Animal Health Corridor and One Health Translational Medicine Initiatives. She is a graduate of Kansas State University (BS Business Administration, Accounting) and serves as an advisory board member for the KSU College of Business.